Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Oxford Biodynamics Plc
Board Change | Company Announcement | Investegate
Oxford BioDynamics Plc announced that Stephen Diggle has stepped down as a Director, having served as Non-Executive Director since October 2016. Vulpes Investment Management, controlled by Diggle, remains the company's largest shareholder and will nominate a new non-executive director. The company thanked Diggle for his support and wisdom over his tenure.
Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling | Journal of Translational Medicine | Full Text
Recent studies suggest that epigenetic dysregulation, particularly DNA methylation, may contribute to the complex pathophysiology of ME/CFS, influencing immune, metabolic, and neuroendocrine functions. Genome-wide methylation analyses using Illumina 450 K and EPIC arrays, as well as reduced representation bisulfite sequencing (RRBS), have identified thousands of differentially methylated positions (DMPs) in patients compared to healthy controls. Trivedi et al.
Oxford BioDynamics Develops a High Accuracy, Discriminating Diagnostic Test for Multiple Canine Cancers
EpiSwitch® Specific Canine Blood (EpiSwitch® SCB) test is a new canine multi-cancer diagnostic test based on OBD’s non-invasive EpiSwitch® array platform Test developed in collaboration with leading US KOL Professor Jaime F Modiano, University of Minnesota, USA Test offers early blood-based detection and discrimination of six high-utility, frequently occuring cancer types: three sarcomas, two lymphomas, and malignant melanoma, each with balanced accuracy of >89% Real-world utility data with...
Oxford BioDynamics PLC Notice of Results (5967X)
Register for streaming realtime charts, analysis tools, and prices.
Oxford BioDynamics PLC OBD strengths commercial leadership
Register to chat with like-minded investors on our interactive forums.
Oxford BioDynamics PLC Bupa UK to cover EpiSwitch(R) CiRT for customers (4448Q)
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Wednesday 18 October 2023 TIDMOBD RNS Number : 4448Q Oxford BioDynamics PLC 18 October 2023 Oxford BioDynamics Plc Bupa UK to cover EpiSwitch(R) CiRT for customers with cancer -- Bupa UK health insurance customers being considered for checkpoint inhibitor immunotherapy will now be offered the smart blood test, which accurately predicts a cancer patient's response to the treatment -- The OBD Bupa UK partnership significantly enhances access to...
Oxford BioDynamics PLC OBD receives reimbursement code for PSE test (4364O)
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Tuesday 3 October 2023 TIDMOBD RNS Number : 4364O Oxford BioDynamics PLC 03 October 2023 Oxford BioDynamics receives reimbursement code for EpiSwitch(R) Prostate Screening (PSE) Test -- EpiSwitch PSE boosts the predictive accuracy of current standard PSA test from 55%, to 94% for determining the presence or absence of prostate cancer -- CPT PLA Code 0433U has been issued to Oxford BioDynamics for insurance reimbursement under Medicare,...
Oxford BioDynamics PLC Half-year Report
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Tuesday 30 May 2023 TIDMOBD RNS Number : 8981A Oxford BioDynamics PLC 30 May 2023 30 May 2023 Oxford BioDynamics Plc ( "OBD" or the "Company" and, together with its subsidiaries, the "Group") INTERIM RESULTS FOR THE SIX-MONTH PERIODED 31 MARCH 2023 Positive momentum on EpiSwitch CiRT, progressing at pace on Prostate Screening EpiSwitch Oxford BioDynamics Plc (AIM: OBD) , a biotechnology company developing precision medicine tests based on the...
Oxford BioDynamics PLC Notice of Interim Results and Investor Webinar
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Tuesday 16 May 2023 TIDMOBD RNS Number : 4918Z Oxford BioDynamics PLC 16 May 2023 Oxford BioDynamics Plc Notice of Interim Results and Investor Webinar Oxford, UK - 16 May, 2023 - Oxford BioDynamics, Plc (AIM: OBD, OBD" or the "Company" and, together with its subsidiaries, the "Group"), a biotechnology company developing precision medicine tests based on the EpiSwitch(R) 3D genomics platform, expects to announce its interim results for the...
Oxford BioDynamics PLC CiRT expanded validation for ICI immunotherapies
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Monday 15 May 2023 TIDMOBD RNS Number : 3371Z Oxford BioDynamics PLC 15 May 2023 Oxford BioDynamics Plc Peer-reviewed study results confirm and expand validation of Oxford BioDynamics' EpiSwitch(R) CiRT blood test for checkpoint inhibitor immunotherapies -- Publication in high-impact journal Cancers describes the development and validation of OBD's EpiSwitch CiRT blood test for predicting individual cancer patient's therapeutic response to...
Oxford BioDynamics PLC US PACT Award for prognosis test for IOrelated HPD
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Tuesday 2 May 2023 TIDMOBD RNS Number : 9807X Oxford BioDynamics PLC 02 May 2023 Oxford BioDynamics Plc Oxford Biodynamics granted US Foundation of NIH PACT Award for prognosis of cancer patients with IO-triggered Hyper-Progressive Disease -- Recipient of a PACT Award worth $963,000 to help reduce to practice a blood-test for prognosis of patients with IO-triggered Hyper-Progressive Disease (HPD) -- HPD is an acute and highly...
Business update for PSE and CiRT tests
We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms. I Agree Wednesday 05 April, 2023 Oxford BioDynamics Business update for PSE and CiRT tests RNS Number : 3939V Oxford BioDynamics PLC 05 April 2023 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Oxford BioDynamics PLC Business update for PSE and CiRT tests
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Wednesday 5 April 2023 TIDMOBD RNS Number : 3939V Oxford BioDynamics PLC 05 April 2023 Oxford BioDynamics Plc Business update - plan to launch Prostate Screening EpiSwitch(R) test by end of 2023; sales progress for flagship EpiSwitch(R) CiRT -- Acceleration of final development and launch of PSE clinical test in both UK and US, for availability in Q4 2023 -- Flagship EpiSwitch CiRT (Checkpoint inhibitor Response Test) continuing to gain...
Oxford BioDynamics PLC Result of AGM
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Thursday 30 March 2023 TIDMOBD RNS Number : 8174U Oxford BioDynamics PLC 30 March 2023 30 March 2023 Oxford BioDynamics Plc ( " OBD " or the " Company " and, together with its subsidiaries, the " Group " ) Result of AGM Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch(R) 3D genomics platform, announces that all resolutions at the Company's...
Oxford BioDynamics PLC AIM Rule 17 Schedule 2(g) Update
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Wednesday 15 March 2023 TIDMOBD RNS Number : 0810T Oxford BioDynamics PLC 15 March 2023 15 March 2023 Oxford BioDynamics Plc ( "OBD" or the "Company" and, together with its subsidiaries, the "Group") AIM Rule 17 Schedule 2(g) Update Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch (R) 3D genomics platform , announces the following information is being...
Oxford BioDynamics PLC Publication of FY22 Annual Report
Oxford Biodynamics (LSE:OBD) Intraday Stock Chart Saturday 4 March 2023 TIDMOBD RNS Number : 9037R Oxford BioDynamics PLC 03 March 2023 3 March 2023 Oxford BioDynamics Plc ( "OBD" or the "Company" and, together with its subsidiaries, the "Group") Publication of 2022 Annual Report Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch (R) 3D genomics platform , today announces that copies of its annual report and...
Stock Market | bentoncourier.com | 501-315-8228
Dr. Steven Mamus, Medical Director of Oncology/Hematology, Cancer Center of Sarasota (FL, US), to present how OBD’s EpiSwitch® CIRT is transforming the way Immune Checkpoint Inhibitor (ICI) therapy is administered to cancer patients This prominent industry event provides an excellent opportunity to present the unique benefit of CiRT to oncologists, pathologists, clinical lab managers, executives, pharma and biotech R&D professionals, and decision-makers at hospitals and healthcare systems...
Oxford BioDynamics PLC OBD to present CiRT clinical utility data at ASCO
TIDMOBD Oxford BioDynamics PLC 05 May 2022 Oxford BioDynamics presents clear clinical utility data of the Checkpoint Inhibitor Response Test (EpiSwitch(R) CiRT) at ASCO 2022, June 3-7 -- EpiSwitch CiRT is a first-of-its-kind precision medicine test that predicts a patient's most likely response to Immune Checkpoint Inhibitor (ICI) therapy -- The Company will be presenting data on a key patient cohort used to develop the EpiSwitch CiRT diagnostic that shows clinical utility across ICI...
Oxford BioDynamics PLC PDMR Dealing
Oxford Biodynamics (LSE:OBD) Historical Stock Chart From Apr 2022 to Jun 2022 TIDMOBD RNS Number : 5279H Oxford BioDynamics PLC 06 April 2022 6 April 2022 Oxford BioDynamics Plc ( "OBD" or the "Company" and, together with its subsidiaries, the "Group") PDMR Dealing Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Paul Stockdale, the Group's Chief Financial Officer and an Executive Director, has purchased 30,000 Ordinary Shares of 1 pence each ("shares") at an...
OBD updates on EpiSwitch CST and CiRT tests
Oxford BioDynamics confirms availability of EpiSwitch® CST (COVID Severity Test) and provides update on clinical validation of EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) OBD's EpiSwitch® CST is currently available in the US and has seen increased interest following the resurgence of COVID-19 from the delta and omicron variants EpiSwitch® CiRT is a blood-based clinical test for predicting a beneficial response to Immune Checkpoint Inhibitor's (ICI's) for Immunotherapies (85%...
Oxford BioDynamics Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing personalized medicine tests based on 3D genomic biomarkers, has signed a Human Material and Data Transfer Agreement with Oregon Health & Science University (OHSU) as part of its EpiSwitch™ COVID-19 disease severity test program. Some people infected with COVID-19 become severely ill and hospitalized, while many only experience mild illness.
Oxford BioDynamics PLC OBD appoints Dr Bartu Ahiska
TIDMOBD Oxford BioDynamics PLC 13 June 2019 13 June 2019 Oxford BioDynamics Plc ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Oxford BioDynamics appoints Dr Bartu Ahiska as Senior Vice President (Commercial) Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces that it has appointed...
Oxford Biodynamics Plc - Medical Equipment - Deals and Alliances Profile [Report Updated: 21-09-2018]
Introduction Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neurodegenerative conditions. Its biomarker discovery platform is used for the detection of aberrant gene expression.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Oxford Biodynamics
Contact Oxford Biodynamics, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack